Alzheimer's disease

Amyloid-Beta Structure Revelation Sheds Light on Leqembi’s Function
Amyloid-Beta Structure Revelation Sheds Light on Leqembi’s Function
BioSpace
Eisai
Biogen
Alzheimer's disease
Leqembi
amyloid beta
Flag link:
JAMA: Leqembi could cost Medicare up to $5B per year
JAMA: Leqembi could cost Medicare up to $5B per year
Medical Marketing and Media
Biogen
Eisai
Leqembi
drug pricing
Medicare
Alzheimer's disease
JAMA
Flag link:
Alzheimer’s doctors see promise, limits in Lilly’s latest drug data
Alzheimer’s doctors see promise, limits in Lilly’s latest drug data
BioPharma Dive
Eli Lilly
donanemab
Alzheimer's disease
physicians
Flag link:
Lilly's Donanemab Data Energizes Alzheimer’s Sector, Safety Concerns Remain
Lilly's Donanemab Data Energizes Alzheimer’s Sector, Safety Concerns Remain
BioSpace
Eli Lilly
Alzheimer's disease
donanemab
Flag link:
For Eli Lilly’s head scientist, Alzheimer’s results cap a 25-year scientific quest
For Eli Lilly’s head scientist, Alzheimer’s results cap a 25-year scientific quest
Stat
Eli Lilly
Alzheimer's disease
Daniel Skovronsky
Flag link:
Lilly drug slows Alzheimer’s decline in large study
Lilly drug slows Alzheimer’s decline in large study
BioPharma Dive
Eli Lilly
donanemab
clinical trials
Alzheimer's disease
Flag link:
Alnylam’s early Alzheimer’s results encourage, but company discloses new hurdle
Alnylam’s early Alzheimer’s results encourage, but company discloses new hurdle
BioPharma Dive
Alnylam
Regeneron
clinical trials
Alzheimer's disease
ALN-APP
Flag link:
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
CNBC
Biogen
earnings
Pharma CEOs
Chris Viehbacher
Eli Lilly
Alzheimer's disease
Leqembi
donanemab
Flag link:
Lilly expects US Medicare to reverse course, fully cover Alzheimer's drugs
Lilly expects US Medicare to reverse course, fully cover Alzheimer's drugs
Reuters
Eli Lilly
Medicare
Alzheimer's disease
Leqembi
Flag link:
FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's disease agitation
FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's disease agitation
Fierce Pharma
Lundbeck
Otsuka
Rexulti
Alzheimer's disease
FDA
Flag link:
Biogen buys into Denali’s amyloid beta program
Biogen buys into Denali’s amyloid beta program
Pharmaphorum
Biogen
Denali Therapeutics
Alzheimer's disease
Flag link:
Lilly says experimental Alzheimer's drug reduces amyloid in small study
Lilly says experimental Alzheimer's drug reduces amyloid in small study
Reuters
Eli Lilly
Alzheimer's disease
clinical trials
remternetug
Flag link:
Coya Therapeutics reports data from Alzheimer’s Disease therapy trial
Coya Therapeutics reports data from Alzheimer’s Disease therapy trial
Clinical Trials Arena
Coya Therapeutics
COYA 301
clinical trials
Alzheimer's disease
Flag link:
Biogen Successfully Targets Tau in Phase Ib Alzheimer's Study
Biogen Successfully Targets Tau in Phase Ib Alzheimer's Study
BioSpace
Biogen
Alzheimer's disease
clinical trials
Flag link:
Otsuka, Lundbeck eye Alzheimer's indication in FDA adcomm for Rexulti label expansion
Otsuka, Lundbeck eye Alzheimer's indication in FDA adcomm for Rexulti label expansion
Endpoints
Otsuka
Lundbeck
Alzheimer's disease
FDA
Rexulti
Alzheimer's disease agitation
Flag link:
Help wanted: Vaxxinity seeks a partner to press ahead with Alzheimer's treatment
Help wanted: Vaxxinity seeks a partner to press ahead with Alzheimer's treatment
Fierce Biotech
Vaxxinity
Alzheimer's disease
clinical trials
UB-311
Flag link:
Neurotechnology company Cognito Therapeutics scores $73M to study Alzheimer's device
Neurotechnology company Cognito Therapeutics scores $73M to study Alzheimer's device
Mobihealthnews
Cognito Therapeutics
Alzheimer's disease
Medtech
funding
neuromodulation
Flag link:
Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
PM Live
Roche
Eli Lilly
Alzheimer's disease
diagnostics
Flag link:
Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO
Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO
Fierce Pharma
Eisai
Leqembi
FDA
CMS
Alzheimer's disease
Flag link:
Alzheimer's Association campaigns for broader Leqembi coverage: report
Alzheimer's Association campaigns for broader Leqembi coverage: report
Fierce Pharma
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:

Pages